Kinase Inhibitor Drugs

A comprehensive resource on case studies of marketed kinase drugs and promising drug trials
Since the discovery of protein kinase activity in 1954, the field of protein kinase drug discovery has advanced dramatically. With the ongoing clinical success of the Bcr–Abl kinase inhibitor Gleevec in the treatment of chronic myelogenous leukemia and seven additional marketed kinase inhibitor drugs, researchers have compelling evidence that kinase inhibitors can be highly efficacious in the treatment of diseases caused by aberrant activity of protein kinase. Currently more than 100 protein kinase inhibitors are in clinical development.
In one comprehensive volume, the editors, Dr. Rongshi Li and Dr. Jeffrey Stafford, present timely and important case studies of marketed kinase drugs and several of the most advanced kinase inhibitors in clinical trials. Kinase Inhibitor Drugs includes:
Case studies from leading investigators and experts in the field that provide firsthand accounts of kinase inhibitor discovery
Current thinking on kinase structure, biochemistry, and signal transduction pathways
Information on state–of–the–art technologies and tools such as structure–based and fragment–based drug discovery
A lineup of clinical–phase growth factor receptor inhibitors
Inhibitors of cell cycle kinases
The discovery of allosteric inhibitors of MEK kinase
Information on pharmacogenomics and its application to kinase inhibitor clinical development

Spis treści:
PREFACE.
CONTRIBUTORS.
PART I GROWTH FACTOR INHIBITORS: VEGFR2, ERBB2, AND OTHER KINASE.
1 Discovery and Development of Sunitinib (SU11248): A Multitarget Tyrosine Kinase Inhibitor of Tumor Growth, Survival, and Angiogenesis (Connie L. Sun, James G. Christensen, and Gerald McMahon).
2 Tykerb Discovery: A Dual EGFR and ERBB2 Tyrosine Kinase Inhibit or (Karen Lackey and G. Stuart Cockerill).
3 Discovery of Pazopanib: A Pan Vascular Endothelial Growth Factor Kinase Inhibitor (Philip A. Harris and Jeffrey A. Stafford).
4 Road to ABT–869: A Multitargeted Receptor Tyrosine Kinase Inhibitor (Michael Michaelides and Daniel H. Albert).
5 Discovery of Motesanib (Andrew S. Tasker and Vinod F. Patel).
6 Discovery of Brivanib Alaninate: A Dual Vascular Endothelial Growth Factor and Fibroblast Growth Factor Receptor Inhibitor (Rajeev S. Bhide and Joseph Fargnoli).
7 S tructure–Based Design and Characterization of Axitinib (Robert S. Kania).
PART II GROWTH FACTOR INHIBITORS: MEK INHIBITORS.
8 Road to PD0325901 and Beyond: The MEK Inhibitor Quest (Judith S. Sebolt–Leopold and Alexander J. Bridges).
9 Discovery of Allosteric MEK Inhibitors (Eli Wallace and James F. Blake).
PART III CELL CYCLE KINASE INHIBITORS: AURORA KINASE AND PLK INHIBITORS.
10 Discovery of MK–0457 (VX–680) (Julian M. C. Golec).
11 Discovery of PHA–739358 (Daniele Fancelli and Jürgen Moll).
12 Discovery of AZD1152: A Selective Inhibitor of Aurora–B Kinase with Potent Antitumor Activity (Kevin M. Foote and Andrew A. Mortlock).
13 Case Study of Aurora–A Inhibitor MLN8054 (Christopher F. Claiborne and Mark G. Manfredi).
14 Discovery of GSK461364: A Polo–like Kinase 1 Inhibitor for the Treatment of  Cancer (Kevin W. Kuntz and Kyle A. Emmitte).
PART IV RELATED SPECIAL TOPICS.
15 Pharmacogenomics of Dasatinib (Sprycel) (Fei Huang and Edwin A. Clark).
16 Practical Use of Computational Chemistry in Kinase Drug Discovery (James M. Veal).
17 Approaches to Kinase Homology Modeling: Successes and Considerations for the Structural Kinome (Victoria A. Feher and J. David Lawson).
18 Fragment–Based Drug Di scovery of Kinase Inhibitors (Daniel A. Erlanson).
19 Protein Kinase Structural Biology: Methods and Strategies for Targeted Drug Discovery (Clifford D. Mol, Kengo Okada, and David J. Hosfield).
INDEX.

Nota biograficzna:
Rongshi Li, PhD, is an Associate Professor in the Drug Discovery Department at H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida.
Jeffrey A. Stafford, PhD, has led drug discovery research at GlaxoSmithKline, Syrrx, and Takeda. He is a co–inventor of the tyrosine kinase inhibitor, pazopanib (Armala).

Okładka tylna:
A comprehensive resource on case studies of marketed kinase drugs and promising drug trials
Since the discovery of protein kinase activity in 1954, the field of protein kinase drug discovery has advanced dramatically. With the ongoing clinical success of the Bcr–Abl kinase inhibitor Gleevec in the treatment of chronic myelogenous leukemia and seven additional marketed kinase inhibitor drugs, researchers have compelling evidence that kinase inhibitors can be highly efficacious in the treatment of diseases caused by aberrant activity of protein kinase. Currently more than 100 protein kinase inhibitors are in clinical development.
In one comprehensive volume, the editors, Dr. Rongshi Li and Dr. Jeffrey Stafford, present timely and important case studies of marketed kinase drugs and several of the most advanced kinase inhibitors in clinical trials. Kinase Inhibitor Drugs includes:
Case studies from leading investigators and experts in the field that provide firsthand accounts of kinase inhibitor discovery
Current thinking on kinase structure, biochemistry, and signal transduction pathways
Information on state–of–the–art technologies and tools such as structure–based and fragment–based drug discovery
A lineup of clinical–phase growth factor rec eptor inhibitors
Inhibitors of cell cycle kinases
The discovery of allosteric inhibitors of MEK kinase
Information on pharmacogenomics and its application to kinase inhibitor clinical development